Purine metabolism in tumorigenesis and its clinical implications

IF 2.5 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2025-09-02 DOI:10.1016/j.seminoncol.2025.152409

Zerui Lu , Jiayi Li , Ying Liu , Hui Li , Ying Sun , Rui Geng , Jiahang Song , Jinhui Liu

{"title":"Purine metabolism in tumorigenesis and its clinical implications","authors":"Zerui Lu , Jiayi Li , Ying Liu , Hui Li , Ying Sun , Rui Geng , Jiahang Song , Jinhui Liu","doi":"10.1016/j.seminoncol.2025.152409","DOIUrl":null,"url":null,"abstract":"<div><div>Metabolic reprogramming constitutes a hallmark of malignant neoplasms. Purine metabolism emerges as a pivotal regulator in cellular metabolic networks through multiple mechanisms, including dysregulation of de novo biosynthesis/salvage pathway coordination, adenosine-mediated immunosuppressive microenvironment formation, and collective contributions to tumorigenesis and malignant progression. During metastatic progression, purine metabolism reinforces tumor cell plasticity through mitochondrial energy regulation and modulation of cell cycle checkpoints (eg, G1/S transition). These mechanistic revelations have positioned purine metabolism-targeting strategies as promising oncotherapeutic candidates. This review methodically analyzes (1) purine metabolic pathways and their regulatory dynamics, (2) adenosine-mediated pathophysiological interactions, and (3) the synergistic impacts of these pathways in malignant transformation. We propose a unified mechanistic framework that clarifies oncogenic purine metabolic rewiring while evaluating translational potential through three clinical dimensions: pathogenesis elucidation, diagnostic biomarker discovery, and targeted therapeutic development. This comprehensive synthesis aims to advance precision oncology through mechanistic insights and therapeutic innovation.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 6","pages":"Article 152409"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775425001010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Metabolic reprogramming constitutes a hallmark of malignant neoplasms. Purine metabolism emerges as a pivotal regulator in cellular metabolic networks through multiple mechanisms, including dysregulation of de novo biosynthesis/salvage pathway coordination, adenosine-mediated immunosuppressive microenvironment formation, and collective contributions to tumorigenesis and malignant progression. During metastatic progression, purine metabolism reinforces tumor cell plasticity through mitochondrial energy regulation and modulation of cell cycle checkpoints (eg, G1/S transition). These mechanistic revelations have positioned purine metabolism-targeting strategies as promising oncotherapeutic candidates. This review methodically analyzes (1) purine metabolic pathways and their regulatory dynamics, (2) adenosine-mediated pathophysiological interactions, and (3) the synergistic impacts of these pathways in malignant transformation. We propose a unified mechanistic framework that clarifies oncogenic purine metabolic rewiring while evaluating translational potential through three clinical dimensions: pathogenesis elucidation, diagnostic biomarker discovery, and targeted therapeutic development. This comprehensive synthesis aims to advance precision oncology through mechanistic insights and therapeutic innovation.

查看原文本刊更多论文

嘌呤代谢在肿瘤发生中的作用及其临床意义

代谢重编程是恶性肿瘤的一个特征。嘌呤代谢通过多种机制在细胞代谢网络中发挥关键调节作用，包括对新生生物合成/挽救途径协调的失调、腺苷介导的免疫抑制微环境的形成以及对肿瘤发生和恶性进展的共同贡献。在转移过程中，嘌呤代谢通过线粒体能量调节和细胞周期检查点（如G1/S转变）的调节来增强肿瘤细胞的可塑性。这些机制的揭示已经定位嘌呤代谢靶向策略作为有希望的肿瘤治疗候选人。本文系统分析了(1)嘌呤代谢途径及其调控动力学，(2)腺苷介导的病理生理相互作用，以及(3)这些途径在恶性转化中的协同作用。我们提出了一个统一的机制框架来阐明致癌嘌呤代谢重布线，同时通过三个临床维度评估转化潜力：发病机制阐明、诊断性生物标志物发现和靶向治疗开发。这一全面的综合旨在通过机制见解和治疗创新来推进精准肿瘤学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.